+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

4-Ipomeanol: a novel investigational new drug for lung cancer



4-Ipomeanol: a novel investigational new drug for lung cancer



Journal of the National Cancer Institute 81(15): 1133-1143



4-Ipomeanol (IPO) is the first agent to undergo preclinical development at the National Cancer Institute (NCI) based principally on a specific biochemical-biological rationale for clinical investigation as an antineoplastic agent targeted against lung cancer. This disease-specific development of IPO was initially stimulated by observations that the compound was activated by metabolism, preferentially within the mammalian lung, specifically within bronchiolar Clara cells, and that its predominant toxicity was to the lung in most species. IPO is inactive or only minimally active against most conventional antitumor test systems. However, some human lung cancer cell lines, as well as a variety of fresh human lung tumor biopsy specimens, have been shown to be capable of mediating the in situ biotransformation of IPO to a potentially cytotoxic intermediate. In this report, the biochemistry, metabolism, preclinical pharmacology, and toxicology of IPO are reviewed and the clinical development plans for this unique and challenging new agent are presented.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039019871

Download citation: RISBibTeXText

PMID: 2664191

DOI: 10.1093/jnci/81.15.1133


Related references

Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone pulmonary metabolism and tumorigenicity in mice by analogues of the investigational chemotherapeutic drug 4-ipomeanol. Chemical Research in Toxicology 5(5): 674-679, 1992

Preclinical toxicology studies of 4-ipomeanol: a novel candidate for clinical evaluation in lung cancer. Cancer Treatment Reports 71(12): 1157-1164, 1987

Metabolic activation and cytotoxicity of 4-ipomeanol in human non-small cell lung cancer lines. Cancer Research 46(7): 3484-3489, 1986

Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer. Clinical Cancer Research 4(9): 2095-2102, 1998

EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer. European Journal of Cancer 33(8): 1173-1176, 1997

Chemical control information on investigational drugs required for an investigational new drug application (I.N.D.). American Journal of Hospital Pharmacy 26(3): 178-179, 1969

Gaining access to investigational drugs for treatment: an investigational new drug application primer. International Journal of Pharmaceutical Compounding 6(4): 271-273, 2002

Dispensing investigational drugs: regulatory issues and the role of the investigational drug service. American Journal of Health-System Pharmacy 61(18): 1882-1884, 2004

Charging for investigational drugs under an investigational new drug application. Final rule. Federal Register 74(155): 40871-40900, 2009

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet. Oncology 16(4): 395-405, 2015

Metallomics for drug development: an integrated CE-ICP-MS and ICP-MS approach reveals the speciation changes for an investigational ruthenium(III) drug bound to holo-transferrin in simulated cancer cytosol. Metallomics 5(8): 955-963, 2013

Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. Journal of Clinical Oncology 22(13): 2576-2586, 2004

Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(9): 1221-1226, 1993

Nci national cancer institute workshop on investigational strategies for detection and intervention in early lung cancer annapolis maryland usa april 21 24 1991. Cancer Research 52(9 Suppl.): 2639S-2768S, 1992

Ipomeanol 4-glucuronide, a major urinary metabolite of 4-ipomeanol in the rat. Drug Metabolism and Disposition: the Biological Fate of Chemicals 10(3): 264-267, 1982